Clinical Drug Experience Knowledgebase

autologous hematopoietic stem cells (2 trials)

autologous mononuclear stem cell (5 trials)

bendamustine (treanda) (3 trials)

bleomycin (blenoxane) (10 trials)

carboplatin (paraplatin) (2 trials)

carmustine (bicnu) (4 trials)

chlorambucil (Leukeran) (1 trial)

cisplatin (platinol) (2 trials)

cyclophosphamide (cytoxan) (24 trials)

cytarabine (cytosar-u) (6 trials)

dacarbazine (dtic-dome) (5 trials)

darbepoetin alfa (aranesp) (1 trial)

doxorubicin (Doxil) (25 trials)

epirubicin (ellence) (1 trial)

etoposide (vepesid) (11 trials)

Filgrastim (neupogen) (2 trials)

fludarabine (fludara) (4 trials)

fludeoxyglucose f-18 (1 trial)

gemcitabine (gemzar) (4 trials)

ifosfamide (ifex) (2 trials)

interferon alpha-2b (Intron-A) (4 trials)

lenalidomide (revlimid) (9 trials)

melphalan (alkeran) (4 trials)

mesna (mesnex) (1 trial)

mosunetuzumab (Lunsumio) (1 trial)

nivolumab (opdivo) (1 trial)

prednisone (meticorten) (19 trials)

procarbazine (matulane) (5 trials)

rituximab (rituxan) (29 trials)

sargramostim (leukine) (4 trials)

stem cells (1 trial)

urea (5 trials)

vinblastine (velban) (5 trials)

vincristine (oncovin) (17 trials)

vindesine (Eldisine) (5 trials)

allogeneic adipose derived mesenchymal stem cell (1 trial)

atezolizumab (Tecentriq) (1 trial)

bortezomib (velcade) (4 trials)

brentuximab vedotin (adcetris) (4 trials)

glofitamab (Columvi) (1 trial)

ibritumomab tiuxetan (Zevalin) (2 trials)

ibrutinib (imbruvica) (2 trials)

inotuzumab ozogamicin (besponsa) (1 trial)

iph4102 (1 trial)

mitoxantrone (novantrone) (1 trial)

obinutuzumab (gazyva) (3 trials)

ofatumumab (arzerra) (1 trial)

oxaliplatin (eloxatin) (3 trials)

ruxolitinib (jakafi) (1 trial)

tislelizumab (1 trial)

valemetostat (Ezharmia) (1 trial)

venetoclax (venclexta) (2 trials)

zarnestra (1 trial)